HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.

Abstract
Novel ruthenium(II) organo-metallic compounds are active in ovarian cancer models [Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human ovarian cancer. Br J Cancer 2002;86(10):1652-7]. [(eta6-C6H5C6H5)Ru(en)Cl]+ (as a PF6 salt, where en=ethylenediamine (RM175)) has been evaluated in a 13-cell line panel. Particular sensitivity (approximately 10-fold lower than mean IC50) was noted in breast cancer and non-small cell lung cancer cell lines. In addition, IC50 in the A549 was 2 microM and RM175 (25 mg kg-1, days 1 and 5, i.p.) caused a significant (p=0.004) growth delay in a xenograft model. HC11 [(eta6-tetrahydroanthracene)Ru(en)Cl]PF6 was more potent in the A549 cell line (IC50 0.5 microM). HC11 (25 mg kg-1, days 1, 8 and 15, i.p.) was also active in vivo. Following RM175 25 mg kg-1, days 1 and 5, and 15 mg kg-1, days 1-5, HC11 25 and 40 mg kg-1, day 1, elevated alanine transaminase levels were detected, suggesting hepatotoxicity. No changes were observed in kidney or haematological parameters. In liver sections, multi-focal hepatic necrosis was seen, becoming confluent at high doses of HC11. In vitro studies confirmed that HC11 was more toxic than RM175 to fresh human hepatocytes and equitoxic to mithramycin. Liver toxicity may be related to the arene ligand and modification may reduce the potential for hepatic toxicity, while maintaining the anti-tumour activity seen.
AuthorsS M Guichard, R Else, E Reid, B Zeitlin, R Aird, M Muir, M Dodds, H Fiebig, P J Sadler, D I Jodrell
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 71 Issue 4 Pg. 408-15 (Feb 14 2006) ISSN: 0006-2952 [Print] England
PMID16360645 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Organometallic Compounds
  • RM175
  • Ruthenium Compounds
  • chloro(eta(6)-tetrahydroanthracene)(ethylenediamine)ruthenium(II)
  • Alanine Transaminase
Topics
  • Alanine Transaminase (blood)
  • Animals
  • Antineoplastic Agents (chemistry, pharmacology, toxicity)
  • Carcinoma, Large Cell (drug therapy, pathology)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Hepatocytes (cytology, drug effects)
  • Humans
  • Inhibitory Concentration 50
  • Injections, Intraperitoneal
  • Liver (drug effects, metabolism, ultrastructure)
  • Lung Neoplasms (drug therapy, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred Strains
  • Mice, Nude
  • Organometallic Compounds (chemistry, pharmacology, toxicity)
  • Ruthenium Compounds (chemistry, pharmacology, toxicity)
  • Weight Loss (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: